Effect of levocarnitine combined with captopril in the treatment of dilated cardiomyopathy complicated with heart failure

doi:10.3877/cma.j.issn.2095-6568.2018.02.011

Abstract

Abstract:

Objective

To study the effect of levocarnitine combined with captopril in the treatment of dilated cardiomyopathy complicated with heart failure.

Methods

A total of 92 patients with dilated cardiomyopathy complicated with heart failure treated in Jiaozhou People's Hospital from April of 2016 to December of 2017 were selected and divided into control group and observation group according to the treatment plans, 46 cases in each group. Both groups received routine anti-heart failure treatment. The control group received levocarnitine injection treatment, and the observation group received levocarnitine injection combined with captopril treatment. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), serum brain natriuretic peptide (BNP), transforming factor-β1 (TGF-β1) levels and MLHFQ scores were compared between the two groups before and after treatment.

Results

After treatment, the LVEF of the observation group was higher than that of the control group, and the LVESD of the observation group was lower than that of the control group (P<0.05). After treatment, the serum BNP level of the observation group was lower than that of the control group, and the serum TGF-β1 level was higher than that of the control group (P<0.05). After treatment, the MLHFQ score of the observation group was lower than that of the control group (P<0.05).

Conclusion

In the treatment of dilated cardiomyopathy complicated with heart failure, levocarnitine injection combined with captopril can effectively improve cardiac function, reduce serum BNP level, improve the level of TGF-β1, and improve the quality of life of patients with dilated cardiomyopathy

Key words: levocarnitine, captopril, dilated cardiomyopathy, heart failure, brain natriuretic peptide, transforming growth factor-β1

Pengyuan Jia, Liang Zhang. Effect of levocarnitine combined with captopril in the treatment of dilated cardiomyopathy complicated with heart failure[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2018, 06(02): 95-98.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxzyxldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-6568.2018.02.011

https://zhxzyxldzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/95

Figures/Tables 3

References 8

[1]	朱继红. 厄贝沙坦联合盐酸曲美他嗪片对扩张型心肌病心力衰竭患者心功能及血清sICAM－1、LPO水平变化的影响[J]. 现代诊断与治疗，2017, 28(23): 4358-4359.
[2]	刘传慧，刘璐，段智霞. 贝那普利联合左卡尼汀治疗扩张型心肌病心力衰竭的临床研究[J]. 现代药物与临床，2017, 32(8): 1445-1448.
[3]	李敏，舒会霞，郭亦杨. 左卡尼汀治疗扩张型心肌病并发心力衰竭34例疗效观察[J]. 陕西医学杂志，2014, 43(5): 612-614.
[4]	万俊茹. 卡托普利与地高辛联用治疗扩张型心肌病心衰的临床分析[J]. 中外医疗，2015, 34(18): 121-122.
[5]	巴拉提·吾马尔. 卡托普利联合地高辛治疗扩张型心肌病致心力衰竭的临床观察[J]. 医疗装备，2016, 29(4): 53.
[6]	原永明，王慧，尹良平，等. 慢性心力衰竭患者BNP、hs－CRP水平检测的临床意义[J]. 检验医学，2015, 30(6): 591-592.
[7]	喻正科，曹丕钢，陈志红，等. 参竹心康汤对慢性心衰大鼠心肌纤维化及TGF－β_1、CTGF表达的影响[J]. 中华中医药学刊，2015, 33(9): 2169-2171.
[8]	张平，张再伟，邵靓. TGF－β1、CTGF对慢性心衰心肌纤维化进展的临床意义[J]. 昆明医科大学学报，2014, 35(11): 45-47.

组别	例数	LVESD(mm)		LVEF(%)
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	46	40.87±5.92	35.89±4.05^a	44.02±3.11	50.17±4.19^a
观察组	46	41.09±5.31	30.46±4.19^ab	43.69±3.49	54.31±4.25^ab

组别	例数	LVESD(mm)		LVEF(%)
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	46	40.87±5.92	35.89±4.05^a	44.02±3.11	50.17±4.19^a
观察组	46	41.09±5.31	30.46±4.19^ab	43.69±3.49	54.31±4.25^ab

组别	例数	TGF－β1		BNP
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	46	189.87±42.18	246.89±50.71^a	708.76±72.48	418.57±51.28^a
观察组	46	192.34±45.82	300.62±54.80^ab	719.58±76.34	357.29±46.37^ab

组别	例数	TGF－β1		BNP
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	46	189.87±42.18	246.89±50.71^a	708.76±72.48	418.57±51.28^a
观察组	46	192.34±45.82	300.62±54.80^ab	719.58±76.34	357.29±46.37^ab

组别	例数	治疗前	治疗后
对照组	46	48.72±8.83	36.24±5.07^a
观察组	46	49.15±8.49	25.19±4.40^ab

Please choose a citation manager

Content to export